Bahija Jallal
Chief Executive Officer chez IMMUNOCORE HOLDINGS PLC
Fortune : 2 M $ au 31/03/2024
Profil
Bahija Jallal is currently the Chief Executive Officer & Director at Immunocore Holdings Plc and Immunocore Ltd.
She is also an Independent Director at Elevance Health, Inc., a Director at Umb Health Sciences Research Park Corp., and an Independent Director at Arrivent BioPharma, Inc. Additionally, she serves as a Director at Anthem, Inc. (DSG), a Trustee at The Johns Hopkins University, and a Council Member at the National Academies of Sciences.
In her former roles, Dr. Jallal was an Independent Director at Guardant Health, Inc. from 2019 to 2022.
She also served as a Non-Executive Director at ADC Therapeutics SA, a Director at Viela Bio, Inc., and Vice President-Drug Assessment & Development at Chiron Corp.
from 2003 to 2006.
From 2006 to 2019, she was the President of MedImmune LLC and Executive Vice President at AstraZeneca PLC from 2008 to 2019.
Additionally, she served as the President of the Association for Women in Science from 2016 to 2018.
Dr. Jallal holds a doctorate degree from Université Pierre et Marie Curie and a graduate degree from Université Paris Diderot-Paris 7.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELEVANCE HEALTH, INC.
0,00% | 01/02/2024 | 3 799 ( 0,00% ) | 2 M $ | 31/03/2024 |
IMMUNOCORE HOLDINGS PLC
-.--% | 16/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
ARRIVENT BIOPHARMA, INC.
-.--% | 26/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Bahija Jallal
| Sociétés | Poste | Début |
|---|---|---|
| ELEVANCE HEALTH, INC. | Director/Board Member | 01/02/2018 |
| IMMUNOCORE HOLDINGS PLC | Chief Executive Officer | 01/01/2019 |
| ARRIVENT BIOPHARMA, INC. | Director/Board Member | 15/02/2022 |
| The Johns Hopkins University | Director/Board Member | 01/01/2014 |
| Umb Health Sciences Research Park Corp. | Director/Board Member | - |
National Academies of Sciences
 National Academies of Sciences Miscellaneous Commercial ServicesCommercial Services The National Academies of Sciences provides advisory services in the areas of science, technology, and health policy. | Corporate Officer/Principal | - |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Chief Executive Officer | 01/01/2019 |
| Anthem, Inc. (DSG) | Director/Board Member | - |
Anciens postes connus de Bahija Jallal
| Sociétés | Poste | Fin |
|---|---|---|
| GUARDANT HEALTH, INC. | Director/Board Member | 15/06/2022 |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ ░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Bahija Jallal
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| GUARDANT HEALTH, INC. | Health Services |
| ELEVANCE HEALTH, INC. | Health Services |
| ADC THERAPEUTICS SA | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
Association for Women in Science
 Association for Women in Science Miscellaneous Commercial ServicesCommercial Services The Association for Women in Science is an organization that supports and recognizes women in science, technology, engineering, and mathematics. The non-profit company is based in Washington. The organization provides a central repository for articles, blogs, press releases, webinars, videos, and newsletters, as well as curated content for women in STEM. The organization also educates about Title IX protections and how to report violations. The AWIS Wall of WISdom provides inspiration and advice from other women in science and STEM. Meredith R. Gibson has been the CEO of the American company since 2022. | Commercial Services |
National Academies of Sciences
National Academies of Sciences Miscellaneous Commercial ServicesCommercial Services The National Academies of Sciences provides advisory services in the areas of science, technology, and health policy. | Commercial Services |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
| Umb Health Sciences Research Park Corp. | |
| Anthem, Inc. (DSG) | |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
